KMB Stock - Kimberly-Clark Corporation
Unlock GoAI Insights for KMB
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $20.06B | $20.43B | $20.18B | $19.44B | $19.14B |
| Gross Profit | $7.18B | $7.03B | $6.22B | $5.99B | $6.82B |
| Gross Margin | 35.8% | 34.4% | 30.8% | 30.8% | 35.6% |
| Operating Income | $3.21B | $2.34B | $2.68B | $2.56B | $3.24B |
| Net Income | $2.54B | $1.76B | $1.93B | $1.81B | $2.35B |
| Net Margin | 12.7% | 8.6% | 9.6% | 9.3% | 12.3% |
| EPS | $7.58 | $5.21 | $5.73 | $5.38 | $6.90 |
Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products worldwide. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The Personal Care segment offers disposable diapers, swimpants, training and youth pants, baby wipes, feminine and incontinence care products, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Depend, Plenitud, Softex, Poise, and other brand names. The Consumer Tissue segment provides facial and bathroom tissues, paper towels, napkins, and related products under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve, and other brand names. The K-C Professional segment offers wipers, tissues, towels, apparel, soaps, and sanitizers under the Kleenex, Scott, WypAll, Kimtech, and KleenGuard brands. The company sells household use products directly to supermarkets, mass merchandisers, drugstores, warehouse clubs, variety and department stores, and other retail outlets, as well as through other distributors and e-commerce; and away-from-home use products directly to manufacturing, lodging, office building, food service, and public facilities, as well as through distributors and e-commerce. Kimberly-Clark Corporation was founded in 1872 and is headquartered in Dallas, Texas.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 13th 2025 | Argus | Upgrade | Buy | $120 |
| November 4th 2025 | Evercore ISI | Downgrade | In-line | $120 |
| August 4th 2025 | JP Morgan | Upgrade | Neutral | $138 |
| July 18th 2025 | Piper Sandler | Resumed | Overweight | $144 |
| January 8th 2025 | TD Cowen | Downgrade | Hold | $145 |
| July 23rd 2024 | TD Cowen | Initiation | Buy | $161 |
| June 24th 2024 | Exane BNP Paribas | Initiation | Neutral | $146 |
| June 13th 2024 | BofA Securities | Upgrade | Buy | $160← $115 |
| June 3rd 2024 | RBC Capital Mkts | Upgrade | Outperform | $165← $126 |
| March 28th 2024 | Evercore ISI | Upgrade | Outperform | $150← $133 |
| March 1st 2024 | Goldman | Resumed | Buy | $135 |
| December 15th 2023 | BofA Securities | Downgrade | Underperform | $115← $135 |
| November 17th 2023 | Piper Sandler | Initiation | Overweight | $146 |
| October 12th 2023 | Bernstein | Upgrade | Market Perform | $118← $125 |
| September 22nd 2023 | HSBC Securities | Initiation | Hold | $133 |
Earnings History & Surprises
KMBEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 20, 2026 | — | — | — | — |
Q1 2026 | Jan 27, 2026 | $1.48 | — | — | — |
Q4 2025 | Oct 30, 2025 | $1.45 | $1.82 | +25.5% | ✓ BEAT |
Q3 2025 | Aug 1, 2025 | $1.67 | $1.92 | +15.0% | ✓ BEAT |
Q2 2025 | Apr 22, 2025 | $1.89 | $1.93 | +2.1% | ✓ BEAT |
Q1 2025 | Jan 28, 2025 | $1.51 | $1.50 | -0.7% | ✗ MISS |
Q4 2024 | Oct 22, 2024 | $1.70 | $1.83 | +7.6% | ✓ BEAT |
Q3 2024 | Jul 23, 2024 | $1.71 | $1.96 | +14.6% | ✓ BEAT |
Q2 2024 | Apr 23, 2024 | $1.63 | $2.01 | +23.3% | ✓ BEAT |
Q1 2024 | Jan 24, 2024 | $1.54 | $1.51 | -1.9% | ✗ MISS |
Q4 2023 | Oct 24, 2023 | $1.59 | $1.74 | +9.4% | ✓ BEAT |
Q3 2023 | Jul 25, 2023 | $1.48 | $1.65 | +11.5% | ✓ BEAT |
Q2 2023 | Apr 25, 2023 | $1.32 | $1.67 | +26.5% | ✓ BEAT |
Q1 2023 | Jan 25, 2023 | $1.51 | $1.54 | +2.0% | ✓ BEAT |
Q4 2022 | Oct 25, 2022 | $1.44 | $1.40 | -2.8% | ✗ MISS |
Q3 2022 | Jul 26, 2022 | $1.32 | $1.34 | +1.5% | ✓ BEAT |
Q2 2022 | Apr 22, 2022 | $1.23 | $1.35 | +9.8% | ✓ BEAT |
Q1 2022 | Jan 26, 2022 | $1.24 | $1.30 | +4.8% | ✓ BEAT |
Q4 2021 | Oct 25, 2021 | $1.65 | $1.62 | -1.8% | ✗ MISS |
Q3 2021 | Jul 23, 2021 | $1.71 | $1.47 | -14.0% | ✗ MISS |
Latest News
Citigroup Maintains Sell on Kimberly-Clark, Lowers Price Target to $95
📉 NegativeBNP Paribas Exane Maintains Neutral on Kimberly-Clark, Lowers Price Target to $110
➖ NeutralLive On CNBC Halftime Report Final Trades: Kimberly-Clark, Thermo Fischer, Wabtec, Berkshire Hathaway B
➖ NeutralArgus Research Upgrades Kimberly-Clark to Buy, Announces $120 Price Target
📈 PositiveTD Cowen Maintains Hold on Kimberly-Clark, Lowers Price Target to $112
📉 NegativeMorgan Stanley Maintains Equal-Weight on Kimberly-Clark, Lowers Price Target to $125
➖ NeutralWells Fargo Maintains Equal-Weight on Kimberly-Clark, Lowers Price Target to $110
➖ NeutralEvercore ISI Group Downgrades Kimberly-Clark to In-Line, Lowers Price Target to $120
📉 Negative'Activist Investors in Kenvue Faced Big Losses. Kimberly-Clark Saved the Day; D.E.
➖ NeutralKimberly-Clark is buying Tylenol maker Kenvue at a 46% premium
📈 PositiveKimberly-Clark to acquire Kenvue in $48.7 billion deal
📈 PositiveKimberly-Clark shares are trading lower after the company announced it will acquire Kenvue in a cash and stock transaction with an enterprise value of approximately $48.7 billion.
📉 NegativeKenvue shares are trading higher after Kimberly-Clark announced plans to acquire the company in a cash and stock deal.
📈 PositiveKimberly-Clark To Acquire Kenvue In Cash And Stock Transaction Valued At Approximately $48.7B Creating Global Health And Wellness Leader With 10 Iconic Billion-Dollar Brands
📈 PositiveJP Morgan Maintains Neutral on Kimberly-Clark, Raises Price Target to $129
➖ NeutralTD Cowen Maintains Hold on Kimberly-Clark, Lowers Price Target to $130
➖ NeutralUBS Maintains Neutral on Kimberly-Clark, Raises Price Target to $132
➖ NeutralKimberly-Clark shares are trading higher after the company reported Q3 results above estimates.
📈 PositiveKimberly-Clark Q3 Adj. EPS $1.82 Beats $1.76 Estimate, Sales $4.150B Beat $4.123B Estimate
📈 PositiveJP Morgan Maintains Neutral on Kimberly-Clark, Lowers Price Target to $127
➖ NeutralFrequently Asked Questions about KMB
What is KMB's current stock price?
What is the analyst price target for KMB?
What sector is Kimberly-Clark Corporation in?
What is KMB's market cap?
Does KMB pay dividends?
Similar Stocks
Consumer Defensive SectorExplore stocks similar to KMB for comparison